In addition, the detection of TTF-1+ and/or CD56+ CTCs clearly revealed the phenotypic heterogeneity of CTCs in patients with SCLC as well as their changes during the different clinical phases of the disease. This evidence concerns the gene NCAM1 and small cell lung carcinoma.